RP
ACET icon

Regeneron Pharmaceuticals’s Adicet Bio ACET Stock Holding History

Regeneron Pharmaceuticals’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523K Hold
60,511
– – 0.3% 3
2026
Q1 		$412K Hold
60,511
– – 0.86% 2
2025
Q4 		$510K Hold
60,511
– – 1.51% 2
2025
Q3 		$784K Hold
60,511
– – 0.11% 4
2025
Q2 		$591K Hold
60,511
– – 0.04% 3
2025
Q1 		$731K Hold
60,511
– – 0.06% 5
2024
Q4 		$931K Buy
+60,511
New +$1.14M 0.09% 4

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Regeneron Pharmaceuticals's ACET Position: Q2 2026 in Review

Regeneron Pharmaceuticals held its Adicet Bio (ACET) position steady in Q2 2026 at 60,511 shares worth $523K. The position accounts for 0.3% of the portfolio, ranked #3.

Regeneron Pharmaceuticals first reported a position in ACET in Q4 2024 and has held it in 7 quarters since. The position peaked at $931K in Q4 2024. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Regeneron Pharmaceuticals held 60,511 shares of Adicet Bio worth $523K as of Q2 2026.
  • Regeneron Pharmaceuticals left its Adicet Bio share count unchanged in Q2 2026.
  • Adicet Bio made up 0.3% of Regeneron Pharmaceuticals's portfolio in Q2 2026, its #3 holding.
  • Regeneron Pharmaceuticals first reported a position in Adicet Bio in Q4 2024 and has held it in 7 quarters since.
  • Regeneron Pharmaceuticals's Adicet Bio position peaked at $931K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2026, filed 7 Aug 2026.